The Effects of Leucine on Body Weight
Primary Purpose
Overweight, Obesity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
L-Leucine 8gr
Liquid meal
L-Leucine 4g
Sponsored by
About this trial
This is an interventional treatment trial for Overweight focused on measuring Leucine, Weight Loss
Eligibility Criteria
Inclusion Criteria:
- 18-65 year old overweight/obese
- healthy men and women
- Body Mass Index (BMI) of 28-35
Exclusion Criteria:
- unusual or extreme dietary or exercise habits
- daily leucine supplement use
- inability to follow instructions to drink liquid meals
- type 1 diabetes or type 2 diabetes on drug treatment(diet controlled diabetics will be enrolled after consulting with their treating physicians)
- hypothyroidism or hyperthyroidism
- chronic wasting diseases (Acquired Immune Deficiency Syndrome (AIDS), cancers, cirrhosis, renal failure, Chronic Obstructive Pulmonary Disease (COPD), heart failure)
- drug or alcohol abuse
- tobacco smoker within the past 6 months
- pregnancy or lactating
- use of medications known to affect carbohydrate or lipid metabolism, satiety, or hunger
- anemia
- abnormal liver function tests (LFTs)
- women who are of child bearing age without adequate birth control modality
Sites / Locations
- Columbia University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
L-Leucine 4grams
L-Leucine 8 grams
L-Leucine 0 grams
Arm Description
This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
Arm number two of the study will be a dose of Leucine of 8g.
The third arm of the study will be composed of a control drink with no leucine in it.
Outcomes
Primary Outcome Measures
Effects on Weight
Weight
Secondary Outcome Measures
Energy Expenditure
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00683826
Brief Title
The Effects of Leucine on Body Weight
Official Title
Effects of Leucine Supplement on Body Weight and Cardiometabolic Changes
Study Type
Interventional
2. Study Status
Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Protein-rich diets appear to show some benefits in promoting weight loss. It is thought that increased intake of leucine may account for some of this effect. This study is designed to assess whether any of the beneficial effects of dietary leucine supplementation observed in mice also apply to humans.
Specifically, our team would like to determine whether oral leucine supplementation in overweight/obese humans increases metabolic rate, reduces body weight, improves glucose utilization and/or, reduces circulating fat levels in the blood. We hope that the results obtained from this pilot study will highlight the specific aspects of metabolic improvement associated with increased daily leucine intake. This study will should provide data that can be used to design more definitive trials with regard to dietary leucine supplementation.
Hypothesis
This pilot study is designed to accomplish the following two goals:
to assess whether any of the beneficial effects of dietary leucine supplementation observed in mice also apply in humans. Specifically, we want to determine whether oral leucine supplementation in overweight/obese individuals' increases basal metabolic rate, reduces body weight, improves glucose tolerance and/or insulin sensitivity, and/or reduces circulating Low-density Lipoprotein (LDL)-cholesterol levels.
To provide data that can be used to design more definitive trials with regard to dietary leucine supplementation.
We hope that the results obtained from this pilot study will highlight the specific aspects of metabolic improvement associated with increased daily leucine intake. This would in turn lead to more rigorous clinical trials involving larger sample sizes, and with diverse populations of different gender, age, and ethnic groups. Future trials may also be directed to determine minimal doses and durations of leucine supplementation that are capable of achieving clinically significant improvement in the cardio-metabolic risk profile in people.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Obesity
Keywords
Leucine, Weight Loss
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
L-Leucine 4grams
Arm Type
Experimental
Arm Description
This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
Arm Title
L-Leucine 8 grams
Arm Type
Experimental
Arm Description
Arm number two of the study will be a dose of Leucine of 8g.
Arm Title
L-Leucine 0 grams
Arm Type
Placebo Comparator
Arm Description
The third arm of the study will be composed of a control drink with no leucine in it.
Intervention Type
Dietary Supplement
Intervention Name(s)
L-Leucine 8gr
Intervention Description
Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
Intervention Type
Other
Intervention Name(s)
Liquid meal
Intervention Description
Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
Intervention Type
Dietary Supplement
Intervention Name(s)
L-Leucine 4g
Intervention Description
Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
Primary Outcome Measure Information:
Title
Effects on Weight
Time Frame
4 weeks
Title
Weight
Time Frame
at the end of each study treatment arm (six weeks)
Secondary Outcome Measure Information:
Title
Energy Expenditure
Time Frame
will be measure at the end of each treatment period (6 weeks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18-65 year old overweight/obese
healthy men and women
Body Mass Index (BMI) of 28-35
Exclusion Criteria:
unusual or extreme dietary or exercise habits
daily leucine supplement use
inability to follow instructions to drink liquid meals
type 1 diabetes or type 2 diabetes on drug treatment(diet controlled diabetics will be enrolled after consulting with their treating physicians)
hypothyroidism or hyperthyroidism
chronic wasting diseases (Acquired Immune Deficiency Syndrome (AIDS), cancers, cirrhosis, renal failure, Chronic Obstructive Pulmonary Disease (COPD), heart failure)
drug or alcohol abuse
tobacco smoker within the past 6 months
pregnancy or lactating
use of medications known to affect carbohydrate or lipid metabolism, satiety, or hunger
anemia
abnormal liver function tests (LFTs)
women who are of child bearing age without adequate birth control modality
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Henry Ginsberg, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
12. IPD Sharing Statement
Learn more about this trial
The Effects of Leucine on Body Weight
We'll reach out to this number within 24 hrs